The author replies: Pollack's description of how his practice functions sounds like an example of the patient-centered medical home and how it should operate. My patient, Mary, would have benefitted from a more comprehensive approach to her care in which everyone involved was providing excellent care in his or her realm of expertise. I agree that working harder will not fix broken systems. Health care providers and their staff will need to go through major learning processes that will take money, time, hard work, and dedication to make this transformation a success. We desperately need the Obama administration to support and fund the efforts to provide this type of care. One lingering concern that needs to be addressed is the potential conflict of interest between physicians' payments and the care they provide to their patients. Even the perception that physicians have a financial disincentive to provide care will erode the primacy of the patient-doctor relationship.
Greenberg rightly points out that primary care is a community that includes not only internists but also family physicians and pediatricians. Each of these groups brings a different orientation to primary care, but all share a commitment to taking full responsibility for the "care" of the patient. It is a community of caregivers with whom I am proud to be identified. My story about Mary was not meant to be a complaint about my career or to reinforce inaccurate stereotypes. It was first and foremost a story about Mary, a courageous woman for whom I had the privilege to care. It was also an attempt to articulate the joys, sorrows, challenges, and ultimately the deep satisfaction that come from this type of work. My hope is that it might inspire and attract medical students to this immensely rewarding profession.
Since publication of her article, the author reports no further potential conflict of interest.
Ovarian Toxicity from Sirolimus
To the Editor: Sirolimus prevents rejection of renal allografts by blocking the mammalian target of rapamycin (mTOR), a signaling pathway known to regulate ovarian function. 1 Sirolimus is being assessed as a treatment for autosomal dominant polycystic kidney disease (ADPKD). Observational data suggest a potential for ovarian toxicity, but this issue has not been evaluated in randomized, controlled trials. 2 In the Suisse ADPKD study (ClinicalTrials.gov number, NCT00346918), a randomized, controlled trial conducted at the University Hospital Zurich from March 2006 through March 2010, we reviewed the occurrence of menstrual-cycle disturbances and the appearance of ovarian cysts 3 in 39 women with ADPKD, an inherited kidney disease that is not known to affect ovarian morphology and function. 4, 5 The trial was conducted in accordance with the principles of the Declaration of Helsinki, the Good Clinical Practice guidelines of the International Conference on Harmonization, and local regulatory requirements. The local medical ethics committee approved the trial protocol. All patients provided written informed consent. A total of 21 women received sirolimus, and 18 received standard care for 18 months. Abdominal magnetic resonance imaging was performed in each patient every 6 months, and ovarian cysts larger than 2 cm in diameter were identified. Oligoamenorrhea was defined as no menstrual period for 3 months or more, or an interval of more than 35 days between menstrual periods. Analyses of prevalence were carried out with the use of exact logistic regression.
Wyeth (now Pfizer) provided the sirolimus but had no role in the trial design or in the collection, analysis, or interpretation of the data or the writing of the manuscript. The authors had full access to the study data and take responsibility for the integrity of the data, the accuracy of the data analysis, and the fidelity of this report to the trial protocol.
Among patients who received sirolimus at a 1) . At more than one visit after randomization, ovarian cysts were detected in 6 patients in the sirolimus group, as compared with 2 in the control group. Differences in cycle disturbances were apparent in patients who were not receiving oral contraceptives; these differences were detected in 8 of 11 patients in the sirolimus group and in 2 of 9 in the control group. However, these differences were less apparent in patients receiving oral contraceptives (3 of 10 in the sirolimus group and 1 of 9 in the control group). Differences between the sirolimus and control groups with respect to the presence of ovarian cysts did not appear to depend on the contraceptive method. Ovarian cysts were detected in 7 of 11 patients who used barrier methods in the sirolimus group and in 3 of 9 who used barrier methods in the control group; they were detected in 5 of 10 patients who used oral contraceptives in the sirolimus group and in 2 of 9 who used oral contraceptives in the control group). Low-dose oral sirolimus appears to increase the risk of menstrual-cycle disturbances and ovarian cysts. Monitoring of sirolimus-associated ovarian toxicity is warranted and might guide clinical practice with the use of mTOR inhibitors. Matthias Braun, M.D.
